Sharecafe

Latest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook

The attached video covers biotech company Immutep's latest news on their Lymphocyte Activation Gene-3 (LAG-3) treatment and outlook for the coming 12 months.

Immutep (ASX: IMM) are global leaders in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories